Discovery through scientific rigor and commitment to innovation

Learn More

Targeted therapy is at the heart of our pipeline

Tolero has a pathway-centric pipeline of investigational agents aimed at targeting abnormalities in cell function in the context of pathway inhibition. Our approach is to develop specific inhibitors of signaling pathways and identify diseases dependent on these pathways.

Learn More

Zella 201 Trial

Late-stage investigations of targeted therapy

Zella 201 is a clinical trial of alvocidib in combination with cytarabine and mitoxantrone (ACM), in adult patients with relapsed or refractory acute myeloid leukemia (AML).

Learn More

Understanding leukemic blast survival through MCL-1 and CDK9 activity

In this target-driven era of treatment for hematologic malignancies, understanding the distinguishing characteristics of leukemic blast subsets* may be a clinical necessity.

*The prevalence of MCL-1–dependent hematologic malignancies is being investigated.